Myungmoon Pharmaceutical Rises 11.35% Amid Deworming Drug (Fenbendazole, etc.) Theme Uptrend

On the 18th, the theme of anthelmintics (including fenbendazole) showed strength, rising 3.44% compared to the previous day, while Myungmoon Pharmaceutical, which is attracting attention as a related stock, surged 11.35% compared to the previous day. Myungmoon Pharmaceutical is known as a comprehensive pharmaceutical company focused on prescription drugs.

[Graph] Price changes of major stocks in the anthelmintic (including fenbendazole) theme



According to preliminary data compiled at 10:31 AM, foreigners are net buying 2,000 shares of Myungmoon Pharmaceutical.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Myungmoon Pharmaceutical’s quant financial score is 7.08, which is lower in stability, profitability, and growth compared to the average of other stocks related to anthelmintics (including fenbendazole). This can be interpreted as Myungmoon Pharmaceutical having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, Aliko Pharmaceutical ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of analysis by the robo algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.